Placebo News and Research

RSS
DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

Kitov announces more data from Phase III trial on the favorable blood pressure effects of KIT-302

Kitov announces more data from Phase III trial on the favorable blood pressure effects of KIT-302

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Men perform wayfinding tasks better than women

Men perform wayfinding tasks better than women

New study suggests that musclin may promote muscle health

New study suggests that musclin may promote muscle health

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Kitov Pharmaceuticals' KIT-302 drug candidate meets primary efficacy endpoint in Phase III clinical trial

Kitov Pharmaceuticals' KIT-302 drug candidate meets primary efficacy endpoint in Phase III clinical trial

New study examines antioxidant effects of pomegranate extract on cardiovascular risk factors

New study examines antioxidant effects of pomegranate extract on cardiovascular risk factors

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

New MSK-led studies on liquid biopsy presented at San Antonio Breast Cancer Symposium

New MSK-led studies on liquid biopsy presented at San Antonio Breast Cancer Symposium

Early promise for pulmonary artery denervation in PAH patients

Early promise for pulmonary artery denervation in PAH patients

Biogen begins ISIS-SOD1 Rx Phase 1/2 clinical study in patients with amyotrophic lateral sclerosis

Biogen begins ISIS-SOD1 Rx Phase 1/2 clinical study in patients with amyotrophic lateral sclerosis

FDA grants Fast Track status to Cardiorentis' Ularitide for treatment of ADHF

FDA grants Fast Track status to Cardiorentis' Ularitide for treatment of ADHF

Findings may lead to new treatment strategy for phobia

Findings may lead to new treatment strategy for phobia

Palatin achieves patient enrollment target in pivotal phase 3 studies of bremelanotide for FSD treatment

Palatin achieves patient enrollment target in pivotal phase 3 studies of bremelanotide for FSD treatment

New class of diabetes drugs differs in efficacy and safety profiles, shows new research

New class of diabetes drugs differs in efficacy and safety profiles, shows new research

Monoclonal antibody reduces relapse rate by 18% in postmenopausal, HR-positive breast cancer patients

Monoclonal antibody reduces relapse rate by 18% in postmenopausal, HR-positive breast cancer patients

VNS technology could help improve lives of people recovering from stroke

VNS technology could help improve lives of people recovering from stroke

Adjuvant denosumab improves disease-free survival for postmenopausal women with early-stage, HR+ breast cancer

Adjuvant denosumab improves disease-free survival for postmenopausal women with early-stage, HR+ breast cancer

Expression of particular estrogen receptor can reinstate lost memory function

Expression of particular estrogen receptor can reinstate lost memory function

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.